Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.48 |
| ▸ | BTN3A1 | O00481 | 7/20 | 0.47 |
| ▸ | TK1 | P04183 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067744 | 0.79 | FGFR1 (0.48) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL20067745 | 0.79 | HPRT1 (0.54) | — | |
| SCHEMBL19885001 | 0.78 | BTN3A1 (0.64) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL19236210 | 0.78 | BTN3A1 (0.64) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL16075700 | 0.75 | BTN3A1 (0.64) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL20067756 | 0.75 | FAP (0.49) | BTN3A1CYP3A4 | |
| SCHEMBL25574764 | 0.75 | FGFR1 (0.56) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL20067742 | 0.75 | BTN3A1 (0.43) | BTN3A1TK1CYP3A4CYP2C9 | |
| SCHEMBL20012086 | 0.75 | TYMP (0.49) | TYMPTK1CYP3A4CYP2C9 | |
| SCHEMBL20012080 | 0.75 | TYMP (0.49) | TYMPTK1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | TYMP, MTAP, PNP | TYMP 1/4885BTN3A1 3376/4885TK1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.